Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod
Executive Summary
A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.